Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH.
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and points of view. Views represented here may not be those of PhRMA, though they are no less key to a healthy dialogue on issues in health care today.
A recent study published in Diabetes Care finds that about one-third of patients with uncontrolled diabetes aren’t taking medication, and almost 20 percent are on inadequate treatment regimens. Proper treatment is not only essential for controlling glucose levels, but also in preventing other complications such as heart or kidney disease that can contribute to increased medical costs.
Researchers from Harvard University looked at extensive data from commercially insured patients spanning over seven years to identify specific patient factors and variation in treatment patterns. The study concluded that over 30 percent of patients had not started diabetes treatment within six months of an elevated blood glucose test and that 18 percent of patients did not have their treatment intensified within six months of an elevated blood glucose test. The rates of initiating and intensifying treatment both increased over time (by 20 percent and 10 percent, respectively).
For diabetes patients, appropriate use of medicines includes initiating and adhering to treatment as recommended by a physician. It may also include intensifying the treatment regimen if a patient shows a lack of response, by either an increase in dose, addition of a new medicine or switching to another type of medicine such as insulin. Delays in the initiation and intensification of therapy is estimated to contribute to at least 200,000 related adverse events per year.
Diabetes costs the U.S. health care system $245 billion annually, and diabetes patients spend an average of $16,752 per year on medical costs. A key aspect of effective diabetes management is appropriate use of medicines to prevent future health complications. Proper adherence to diabetes medicine is estimated to generate $8 billion in savings per year from avoided hospitalizations.
This study demonstrates that there is significant opportunity for improvement in care for diabetes patients. Better treatment patterns can decrease associated complications and mortality rates, and ultimately lower overall medical spending.
Lauren Gilstrap, MD, MPH is an Assistant Professor of Health Policy at The Dartmouth Institute and an advanced heart disease and cardiac transplantation attending at Dartmouth-Hitchcock Medical Center. She obtained her medical degree from Harvard Medical School and her Masters in Public Health from the Harvard T.H. Chan School of Public Health. Dr. Gilstrap’s current research focuses on quality measurement and improvement for chronic, cardiometabolic disease. She also evaluates the impact of alternative payment programs on patient outcomes and the diffusion of novel therapies and technologies across health systems.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Celebrating advances in diabetes research
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
Did the administration consider the value of innovative diabetes medicines in price setting process?
What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
4 key facts on medicine prices and spending
Insulin and reconciliation
CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018
3 factors impacting medication adherence for patients with diabetes
New insulin report highlights how incentives benefit middlemen, harm patients
Sharing rebates can improve access to medicines and increase health equity
Guest post: H.R.3 is the wrong approach to help patients like me
Guest post: Sharing discounts and rebates is the right thing to do
Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022
Ask About Adherence: Improving adherence among osteoporosis patients could save up to $6.52 billion
Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence
New report shows more than 160 medicines in development for diabetes and related conditions
Five key facts about the market for insulins
Ask About Adherence: Poor medication adherence leads to negative health outcomes and increased health care costs
Six key facts about the market for insulins
Ask About Adherence: Taking adherence research to a global level
Reality check: Value-based contracts are good for patients
Ask About Adherence: Private-sector collaboration can lead to savings and care improvement
New report shows better diabetes management saves money and improves patient outcomes
Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes
Protect your health: Important disaster preparedness tips for Harvey and Irma
Ask About Adherence: Discussion on medication adherence as national priority
Ask About Adherence: Q&A on appointment-based medication synchronization
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
Ask About Adherence
Diabetes
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment
Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment